Advertisement
ROCHELLE, Va., July 18, 2018 /PRNewswire-PRWeb/ -- NDA Partners Chairman Carl Peck, MD, announced today that Scott Brittain, PhD, a pharmacokinetics/pharmacodynamics (PKPD) modeling and simulation expert with more than 14 years of R&D pharmaceutical experience in developing PKPD strategies for clinical research programs, clinical trial modeling and simulation, and clinical study design and analysis, has joined the firm as an Expert Consultant.
Dr. Brittain was formerly Head of Clinical Research and Human Pharmacology, Head of Clinical Pharmacokinetics, and Head of Bioanalytical Sciences at Supernus Pharmaceuticals, Inc. In his early career, he was Head of Bioanalytical Sciences at Eno River Labs (Triangle Laboratories) and Assistant Professor of Chemistry at Georgia College and State University.
"Dr. Brittain's expertise in developing PKPD strategies for clinical research programs, clinical trial modeling and simulation, and clinical study design and analysis will be invaluable to our clients in the early drug development process," said Dr. Peck. "We are very pleased to welcome him to NDA Partners."
Dr. Brittain earned a Doctorate in Chemistry from Harvard University and a Bachelor of Science in Chemistry from the University of Alabama. He has co-authored numerous publications and presentations published in the journals Science, Nature, Neurology, Epilepsy and Behavior, and Acta Neurologica Scandinavica.
About NDA Partners NDA Partners is a life sciences management consulting firm focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Principals and Premier Experts of NDA Partners include three former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and management of client product development programs.
Contact Earle Martin, Chief Executive Officer Office: 540-738-2550 [email protected]
SOURCE NDA Partners, LLC
Advertisement
Dr. Brittain was formerly Head of Clinical Research and Human Pharmacology, Head of Clinical Pharmacokinetics, and Head of Bioanalytical Sciences at Supernus Pharmaceuticals, Inc. In his early career, he was Head of Bioanalytical Sciences at Eno River Labs (Triangle Laboratories) and Assistant Professor of Chemistry at Georgia College and State University.
"Dr. Brittain's expertise in developing PKPD strategies for clinical research programs, clinical trial modeling and simulation, and clinical study design and analysis will be invaluable to our clients in the early drug development process," said Dr. Peck. "We are very pleased to welcome him to NDA Partners."
Dr. Brittain earned a Doctorate in Chemistry from Harvard University and a Bachelor of Science in Chemistry from the University of Alabama. He has co-authored numerous publications and presentations published in the journals Science, Nature, Neurology, Epilepsy and Behavior, and Acta Neurologica Scandinavica.
About NDA Partners NDA Partners is a life sciences management consulting firm focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Principals and Premier Experts of NDA Partners include three former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and management of client product development programs.
Contact Earle Martin, Chief Executive Officer Office: 540-738-2550 [email protected]
SOURCE NDA Partners, LLC
